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                                                EVALUATION  OF  CLINICORADIOLOGICAL  PULMONARY  
MANIFESTATIONS IN  TYPE 2  DIABETES MELLITUS  AND CORRELATION  BETWEEN PULMONARY 
FUNCTION TEST AND GLYCEMIC CONTROL. 
BACKGROUND:  
Diabetes mellitus is increasing in global prevalence with India having more than 50 million diabetic 
population. Diabetes mellitus causes the lungs to deteriorate quicker than they do normally with age 
Impaired immune response in diabetes can cause recurrent infections .Higher blood sugar result in 
diabetic microangiopathy and non enzymatic  glycosylation of tissues causing alveolar basement 
membrane thickening,deposition in collagen of chest wall and bronchial tree causing muscle 
weakness.This result in decrease gas transfer,diminished lung function and air flow limitation.There are 
very few data regarding pulmonary function in type2 diabetes especially in Indian population. 
 AIM OF STUDY 
1) Correlation between pulmonary function in diabetic patients based on PFT values and glycemic 
control  
2) Various clinical and radiological pulmonary manifestations in diabetes mellitus 
         MATERIALS & METHODS: 
                         Prospective study of 150 patients was carried out  in Thoracic medicine 
department,Madras Medical College over  8months. All patients with age more than 30 years with 
proven Type II diabetes mellitus  with or without respiratory symptoms/signs were included.Diabetic 
status assessed by FBS,PPBS,HbA1C .Chest X ray, Sputum AFB, gram stain,C&S, fungal smear and 
culture,Mantoux were done.PFT  was done in patients and  control population.All findings correlated 
with duration of diabetes and glycemic control 
       RESULTS 
 
Of the 150 patients in the study group 91 were males and 59 were females.60% of the study group were 
symptomatic ,of which 37.3% were males & 22.7% were females. Of the symptomatics (n=90),50% had 
pulmonary tuberculosis,33.3% had other bacterial and fungal infections , 16.6% had no active infection,60% 
mantoux negative & 40% were mantoux  positive. Of the pulmonary TB patients 71.1% were sputum positive & 
28.8 % were sputum negative.65.6%  of sputum positive were mantoux  positive. Radiologically most common 
finding in pulmonary TB was lower lung field TB. Klebsiella pneumonia was the most common bacterial 
infection other than TB. Pulmonary function tests were done in 60asymptomatics & 15 symptomatics without 
active infection and 75 age and sex matched control population .FEV1 and FVC showed statistically significant 
reduction in diabetics compared to non diabetic controls .Decrease in FEV1 and FVC correlated with duration 
of diabetes ,but not with HbA1C levels. 
Key words:diabetes mellitus,non enzymatic glycosylation,FEV1,FVC,HbA1C 
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I	TRODUCTIO	 
Diabetes mellitus is a disease that is increasing in epidemic 
proportion in asian countries with India having more than 50 million 
diabetic population. It is estimated to affect 336 million people world 
wide by 2050 with 7 million new diabetic cases. Diabetes mellitus is 
associated with widespread metabolic, hormonal and micro vascular 
abnormalities as well as disturbance of function of organ systems. 
Lung can be involved in the pathogenesis of diabetes and can be 
considered as another end organ adversely affected by diabetes. It can 
cause premature aging of lungs. Higher blood sugar level result in  
Diabetic microangiopathy and non enzymatic glycosylation of tissue 
proteins causing alveolar epithelium basement membrane thickening.  
Glycosylation can also cause deposition in collagen of chest wall and 
bronchial tree causing muscle weakness. This result in decrease gas  
transfer, diminished lung function and air flow limitation. Diabetes 
can also lead to autonomic neuropathy. Impaired immune response in 
diabetes can cause recurrent bacterial pneumonia, fungal infections 
and Tuberculosis. 
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Diabetes is an independent risk factor for tuberculosis both drug 
sensitive and multidrug resistant. 
There are many studies showing pulmonary function in type 
1diabetes mellitus, but very few data regarding pulmonary function in 
type2 diabetes especially in Indian population. 
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AIM OF STUDY 
1. To study the various clinical and radiological pulmonary  
manifestations in diabetes mellitus.  
2. To study the correlation between pulmonary function in diabetic 
patients based on PFT values and glycemic control assessed by FBS , 
PPBS, HbA1C. 
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REVIEW OF LITERATURE 
Diabetes mellitus is a group of metabolic diseases characterised 
by hyperglycemia resulting from defects in insulin secretion, insulin 
action or both. Chronic hyperglycemia in long standing diabetes is 
associated with long term damage and dysfunction in various organ  
systems of the body. 
Two types of diabetes are type1 diabetes mellitus and type 2 
diabetes mellitus. 
Type1 diabetes mellitus: 
It presents most often in younger patients. It is less common 
than Type2 diabetes mellitus. It is caused by absolute deficiency of 
insulin secretion due to autoimmune pathologic process in pancreatic 
islets against islet cell cytoplasmic protiens. 
Type2 diabetes mellitus : 
Most common type, adult onset disease caused by insulin 
resistance and inadequate compensatory insulin response. In type 2 
diabetes mellitus degree of hyperglycemia is sufficient to cause 
pathologic and functional changes in target tissues and may be present 
for a long period of time without clinical symptoms before diabetes is  
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detected. Major morbidities in type 2 diabetes are due to its 
microangiopathic complications. 
There are many studies showing that lung is a target organ in 
diabetes mellitus and poor glycemic control is a strong determinant of 
reduced pulmonary function in type2 diabetes. 
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Pulmonary complications in diabetes mellitus 
1) pulmonary infections 
2) Pulmonary function abnormalities 
3) Abnormal basal airway tone 
4) Unexplained dyspnoea due to phrenic neuropathy causing 
diaphragmatic palsy 
5) Obstructive sleep apnoea and other patterns of disordered breathing 
during sleep 
6) Pulmonary hypertension  
7) In diabetic ketoacidosis increased predisposition to ARDS 
8) New born babies of diabetic mothers –neonatal respiratory distress 
syndrome. 
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PULMO	ARY I	FECTIO	S I	 DIABETES 
Chronic hyperglycemia in diabetes can lead to alterations in host 
defence mechanisms and local lung defence mechanism by altering 
function of respiratory epithelium and ciliary motility. 
Characteristics of pulmonary infection in diabetes 
Longer duration of infections 
Recurrent bacterial pneumonias 
Severity of clinical presentation 
Severe complications 
Increased morbidity & mortality 
Pathogenesis of pulmonary infections in diabetes 
Hyperglycemia in diabetes impairs function of neutrophils and  
monocytes.It affects  *chemotaxis 
*adherence 
*phagocytosis 
*ability of intracellular microbial killing. 
Levels of serum complem
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NADPH is normally generated by hexose monophosphate shunt 
pathway 
 
In diabetes, hyperglycemia lead to more glucose entering the 
cells which is metabolised by the polyol pathway. This pathway 
converts glucose to sorbitol by aldose reductase enzyme, which 
requires NADPH. 
As a result of this two major consequences occur. 
1) Elevated sorbitol levels can lead to complications in diabetes. 
2) Competition for NADPH results in decreased production of free 
radicals by oxidative burst and reduces intracellular killing of 
microbes. 
  
Chronic hyperglycemia a
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Diabetic gastroparesis can increase the risk of aspiration in diabetes. 
Abnormality in ciliary motility also adds to impaired clearance 
mechanisms and predispose to infections. In response to infection and 
cytokine release, insulin resistance occurs in peripheral tissues and 
results in blood sugar elevation. 
Common respiratory infections in diabetes mellitus 
Staphylococcus aureus infections and gram negative bacterial 
infections are seen with increased frequency in diabetes. 
Streptococcus pneumonia, Legionella pneumophila, Viral infections 
are associated with increased morbidity in diabetes. 
Staphylococcus aureus infections 
Due to increased nasal carriage of staphylococcus aureus in 
uncontrolled diabetics, they are more prone for staphylococcal 
pneumonia and its complications. This nasal carriage is influenced by 
degree of glycemic control. 
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Gram negative aerobic infections 
In diabetics gram negative aerobes have an increased adherence 
and thus increased rate of colonisation in upper airways. This leads to 
increased predisposition to infection in them. 
Anaerobic pulmonary infections 
Anaerobic infections are more common in diabetics due to  
1. altered clearance mechanisms 
2. altered cough mechanism 
3. disorders of oesophagus 
4. hypoglycemic seizures causing depressed mental status 
5. changes in microcirculation causing decreased oxygen supply 
predisposing to anaerobic infections 
Streptococcus pneumonia 
Group B streptococcus pneumonia is the most severe 
microorganism causing infection in diabetes. It is a risk factor for the 
development of bacteremia in pneumococcal pneumonia resulting in 
mortality. So immunization against pneumococci is advised in 
diabetes. 
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Viral pneumonia  
Increased predisposition for influenza virus pneumonia is seen 
in diabetes, associated with increased morbidity and mortality. 
Influenza epidemics are associated with increased rate of pneumonia 
in diabetics, increased chance of diabetic ketoacidosis and increased  
mortality, so prophylactic influenza vaccine is advised in diabetics. 
Fungal pneumonia 
Fungal pneumonias are more common in diabetics. Most common 
fungal infection is aspergillus infections. 
	osocomial pneumonia 
Usually nosocomial pneumonia in diabetics are caused by 
Staphylococcus aureus and gram negative aerobes. Klebsiella 
pneumonia and Staphylococcal infections are associated with more 
severe clinical course. 
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Complications of pneumonia in diabetics. 
Non resolving pneumonia 
Recurrent pneumonia 
Parapneumonic effusion 
Empyema 
Bacteremia 
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Tuberculosis in diabetics 
Causes for increased predisposition for tuberculosis in diabetics 
1. Association between HLA DRB1 and HLA DQB1 and 
pulmonary tuberculosis complicated with diabetes. HLA DRB1 
increases susceptibility to pulmonary TB in diabetes .HLA 
DQB1 is protective for pulmonary TB in diabetes.  
2. neutrophilic dysfunction  
3. impaired cytokine production  
4. decreased interferon α production capacity  
5. decreased production of Interleukin 1β and tumor necrosis 
factor α 
6. non enzymatic glycosylation of tissue proteins causing 
alterations in connective tissue and increased susceptibility to 
TB. 
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Clinical presentation of pulmonary TB in diabetes 
Tuberculosis in diabetes is usually due to reactivation of old 
focus of infection. It occurs as more advanced disease with lower lung 
field involvement and consolidatory changes than usual.  
Cavitatory lesions are more common. Cavities are large about 
2-4 cm in an area of consolidation. American thoracic society and 
centre for disease control considers diabetes as a special situation and 
prescribe chemoprophylaxis with isoniazid in diabetics with positive 
mantoux test. 
Patients with active tuberculosis are at more risk of developing 
diabetes mellitus. Possible explanations for these are 
1. In active pulmonary TB-immuno reactive insulin, C-peptide, 
glucose levels before and after glucagon stimulation shows 
absolute insulin deficiency and more frequent development of 
severe diabetes 
2. Functional disorders of the insular system of pancreas more 
evident in middle aged and elderly with pulmonary tuberculosis. 
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3. Tuberculous pancreatitis-a chronic pancreatitis of tubercular 
origin may be revealed only with the development of diabetes 
mellitus. 
Consequences of co-existing tuberculosis and diabetes 
1. Type 2 diabetes involving high blood sugar levels is associated 
with altered immune response to tuberculosis. 
2. These patients take longer time to respond to anti TB treatment. 
3. Patients with active TB and Diabetes are more likely to develop 
multidrug resistant tuberculosis. 
4.  Active tuberculosis patients with diabetes should be treated 
with Insulin 
Problems in treatment of co-existing tuberculosis and diabetes are 
1. Anti tuberculosis drugs affect the beta cell function of pancreas 
and unmask the diabetic status of the patients.  
2. Rifampicin is a potent hepatic enzyme inducing agent that 
accelerates the metabolism of oral hypoglycemic agents. This 
causes early hyperglycemia and increases insulin requirement in 
tuberculosis patients.  
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3. Biguanides (Metformin) has anorectic action, causes 
malabsorption. This causes weight loss, exaggerating the weight 
loss already caused by TB.  
4. Sulfonyl ureas are also not indicated in patients taking ATT.  
5. Indication for withholding OHA in diabetes  patients with TB - 
Marked weight loss 
- Increasing age 
- Longer duration of diabetes 
- Higher insulin and caloric needs in TB.  
6. Use of insulin jet injector in diabetes increases the risk of 
Mycobacterium Chelonae infection. 
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Pulmonary function abnormalities in diabetes 
1. Decreased vital capacity  
2. Decreased total lung capacity.  
3. Decreased pulmonary elastic recoil. 
4.  Impaired alveolar gas exchange  
5. Decreased DLCO  
6. Decreased maximal oxygen uptake  
7. Decreased inspiratory muscle strength  
8. Peripheral airway dysfunction  
9. Abnormal basal airway tone due to alteration in vagal 
pathway caused by diabetic autonomic neuropathy. This 
leads to decreased bronchial reactivity and reduced 
bronchodialation. 
Pathogenesis of pulmonary function abnormalities in diabetes 
Development of lung abnormalities in diabetes are due to 
alterations in lung connective tissue at biochemical level. All these 
changes are brought about by non enzymatic glycosylation of tissue 
proteins and pulmonary microangiopathy. In healthy non smokers 
usual rate of decline in FEV1 is 25-30 ml/year. In long standing 
diabetes decline can be up to 71 ml/year. 
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	on enzymatic glycosylation of proteins 
Enzymatic addition of any sugar to a protein is called 
glycosylation and non enzymatic process is called glycation. 
Hyperglycemia leads to glycation of proteins in the body. Glucose 
forms Schiff base with N- terminal amino group of proteins. Glucose 
molecule first attaches to N-terminal amino group by an aldimine 
linkage. Once attached glucose is not removed from haemoglobin in 
RBC. They remain throughout the life span of RBC,120 days. 
 
                   	O	 E	ZYMATIC GLYCOSYLATIO	 
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Glycation also occurs in albumin, collagen etc. Glycated tissue 
proteins such as collagen are called advanced glycation end products. 
Glycation of matrix proteins once occurred is completely irreversible. 
They are further condensed to heterocyclic imidazole derivatives. 
Accumulation of advanced glycation end products lead to cross 
linking of matrix proteins with altered function. Rate of formation of 
advanced glycation end products is proportional to square of glucose 
concentration. 
Normal elastance and compliance of lung require all connective 
tissue elements in harmony and proper spatial orientation. Strength 
and stability of connective tissue is provided by cross link formation 
of both collagen and elastin components. 
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Structural changes in lung parenchyma in diabetes 
1. Narrowing of alveolar space  
2. Flattening of alveolar epithelium  
3. Expansion of interstitium  
4. Involvement of pulmonary vessel  
5. Involvement of basement membrane of alveolar epithelium, 
bronchial epithelium and pulmonary capillaries. 
Histological changes occurring in the lungs are of two types 
• Increased amounts of collagen and elastin causing thickening of 
basement membrane of alveoli and pulmonary alveolar wall 
thickening. 
• Due to fibroblast proliferation and deposition in capillary 
endothelium , thickening of basement membrane of capillaries. 
So impairment in alveolar capillary membrane occurs which causes 
increase in distance and time of gas exchange between alveoli and 
RBC in pulmonary capillaries. Barrier thickening lead to decreased 
oxygen saturation in erythrocytes. 
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There are several studies using electron microscope that shows 
thickening of basal lamina is of same magnitude in lung and kidney. 
In early stages of diabetes this lung damage may be subclinical. 
Diabetes can affect the strength and endurance of muscles of 
respiration especially diaphragm. It also causes deleterious effects in 
collagen structure of lung parenchyma and chest wall cartilage. These 
changes limit motility of chest wall. 
Peripheral airway dysfunction can occur in diabetes. A sensitive 
index for this is forced oscillation. It is a non invasive equivalent of 
dynamic lung compliance. It measures respiratory resistance during 
resting breathing and detects early inflammation in peripheral airway 
disease. 
Impaired lung function can cause diabetes mellitus. Patients with 
reduced lung function are at increased risk of developing insulin 
resistance and hyperinsulinemia. Impaired lung function that is 
decrease in FVC and FEV1 can be risk factors for glucose intolerance, 
resistance to insulin and type2 diabetes mellitus. This may be due to 
effect of hypoxemia in glucose and insulin regulation and also due to 
inflammatory mediators in lung and its effect of signalling on insulin. 
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Various pulmonary functions like airflows and lung volumes, 
respiratory muscle strength, ventilation & perfusion relationship, 
diffusion and gas exchange in diabetes can be measured by 
spirometry, body plethysmography, nitrogen wash out, carbon 
monoxide diffusing capacity DLCO measurements in diabetics. 
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Spirometry  in diabetes 
Spirometer was invented by John Hutchinson to measure what 
he called vital capacity that is capacity to live. Since then it has 
become an important aspect of evaluation of respiratory disease. It 
assess lung volumes and airflows during inspiration and expiration. So 
it is a simple expression of a complex process just like measuring 
blood pressure. 
There are several studies suggesting that pulmonary dysfunction 
may be one of the earliest measurable non metabolic alteration in 
diabetes. Mastubara & Hara et al (40) studies on pulmonary function 
and changes in microscopic structure of lungs in diabetics show 
significant decrease in Forced vital capacity, total lung capacity, 
residual volume in diabetics compared to control group. 
Makkar P et al (36) also showed various changes in pulmonary 
function in the form of decline in FVC, peak expiratory flow, mid 
expiratory flow 75% in diabetes. 
Mckeever et al showed that decrease in FEV1, FVC is 
associated with increase in HbA1c levels. Singh et al (1995) found 
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significant reduction in forced vital capacity in diabetes but no change 
in FEV1, PEFR. 
Asanuma et al (16), Lange et al, Boulber et al have reported that 
FVC, FEV1 are reduced in diabetes compared to controls. Rosenecker 
et al showed decline in pulmonary function in diabetes over a 5 year 
period. Davis et al (38) also reported decline in FVC,FEV1 in 
diabetics. 
Indications of spirometry in diabetes 
• Mandatory lung function monitoring in diabetics every two 
years 
• Diabetic patients with history of cough, unexplained dyspnoea, 
chest pain ,wheezing, smoking history  
• Diabetics with abnormal chest x-ray, arterial blood gas values  
• Screening of lung function in those diabetics with abnormal 
blood sugar and HbA1c levels.  
• Preoperative risk assessment in diabetics 
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Contraindications of spirometry in diabetics 
• Hemoptysis.  
• dizziness, headache, nausea, vomiting.  
• recent upper abdominal, thoracic surgeries.  
• recent history of eye surgeries, glaucoma. 
•  recent history of severe chest pain, unstable angina, myocardial 
infarction  
• thoracic aneurysm, pneumothorax.  
Spirometry can be done by flow sensing or volume displacement  
Spirometers. 
American thoracic society recommends that equipment should be 
such that  
• it can be calibrated with a 3 litre syringe 
• it should record atleast FEV1 and FVC  
• It should record a flow volume curve or loop 
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Spirometry manoeuvre 
 Expiratory manoeuvre -done by taking a full deep breath from 
the spirometer and then holding the mouth piece between lips to create 
a good seal, patient has to expire hard and fast as possible until no  
breath is left. 
Expiratory and inspiratory manoeuvre-breathe in and out for 2-3 
tidal breaths, then expire as fast as possible until no breath is left. 
Patient has to inspire rapidly to maximum capacity. Patient should be 
encouraged continuously to ensure best effort. 
Acceptable tests- 
  Effort should be maximum, smooth and cough free. 
  Exhalation time should be atleast 6 seconds 
  Reproducibility as indicated by FVC should be within 5% or 
100ml between highest and next best test among three acceptable 
tests. Best value among three is selected. 
 
Spirometry 
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can be used as a simple non invasive method to estimate pulmonary 
capillary damage in diabetes. 
Mori et al (15) showed decreased carbon monoxide diffusion 
capacity in diabetics as duration of diabetes increases. Asanuma et al 
(16) also showed negative correlation between DLCO and diabetes 
duration. Schuyler et al showed decreased DLCO in younger Type 1 
diabetics. Schernthaner et al (5) in contrast showed no significant 
impairment in DLCO in diabetes. 
DLCO can be measured by single breath or steady state 
methods. These methods are based on fick’s law of diffusion. 
Glycosylated haemoglobin and pulmonary function 
HbA1C serves as an index of glycemic control over a period of 
4 weeks to 3 months. There are several studies showing increased  
HbA1C values associated with decline in lung function in diabetics. 
Every 1% increase in HbA1C can cause 4% decline in FVC. Moris et 
al (15) studies in contrast showed no relationship between HbA1C and 
pulmonary function. 2010 American Diabetes Association has fixed 
HbA1c levels > 48mmol/mol or >or = 6.5% as another criteria for 
diagnosis of diabetes. 
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Techniques to measure HbA1C include  
 High performance liquid chromatography  
 Immunoassay  
 Enzymatic assay  
 Capillary electrophoresis 
Duration of diabetes and pulmonary function 
Due to an increase in the duration of diabetes mellitus (DM), 
thickening of the capillary basal membrane, increase in capillary 
permeability, blood flow and viscosity and disturbances in the 
functions of platelets may be observed in diabetics, particularly in the 
ones who are genetically susceptible. Schuyler described significant 
decline in transpulmonary pressure at 50 and 60% of total lung 
capacity (TLC) and decreased TLC type I diabetes patients. He 
concluded that the observed decreases in lung recoil pressure at these 
lung volumes were due to premature aging of lung elastic elements as 
a result of longer duration of diabetes. Mori showed that DLCO% was 
decreased significantly with increase in duration of diabetes and the 
reduction was greater in patients with diabetic microangiopathy 
(especially nephropathy) and in those on insulin treatment. Other 
Pulmonary function tests showed no relationship. Sandler et al 
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concluded that 60% of a diabetic population had abnormal pulmonary 
function, mild reduction of lung elastic recoil and/or a reduction in 
pulmonary capillary blood volume. The degree of pulmonary 
dysfunction was correlated with the duration of DM. 
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MATERIALS A	D METHODS 
TYPE OF STUDY 
This is an Observational study done to evaluate the various 
pulmonary manifestations in type2 diabetes mellitus patients. 
STUDY PERIOD 
The study was done during a period of 8 months from march 
2012 to October 2012. 
STUDY POPULATIO	 
150 Type 2 diabetes patients 
STUDY CE	TRE 
The study was done at the Department of Thoracic medicine 
and Department of Diabetology, Madras medical college& Rajiv 
Gandhi Government General Hospital, Chennai. 
Proforma was designed, Ethical committee clearance was 
obtained. The nature and purpose of study was explained in detail to 
the study population. Written informed consent was obtained from all 
patients included in the study. 
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I	CLUSIO	 CRITERIA: 
All patients with age more than 30 years with proven Type 2 
diabetes mellitus with or without respiratory symptoms/signs were 
included in the study. 
EXCLUSIO	 CRITERIA:  
 Known case of any obstructive or restrictive lung diseases  
 Smokers  
 Other immune compromised state or malignancy  
 Known heart disease, Chronic kidney disease, Liver disease  
 Patients not giving consent for the study  
 Patient too ill to participate in the study 
STUDY PROCEDURE 
Patients with proven diabetes mellitus with or without 
respiratory symptoms  fulfilling the inclusion criteria were included in 
the study. The following investigations were done in all the study 
population 
1. CBC 
2. FBS, PPBS, HbA1C  
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3. Chest X-Ray 
4. Mantoux test 
5. ECG 
6. ECHO 
For those with respiratory symptoms 
7. Sputum AFB 
8. Sputum gram stain  
9. Sputum   C&S 
10. Fungal smear and culture 
Glycemic control was assessed by fasting blood sugar, post 
prandial blood sugar and HbA1c values.HbA1C was measured by 
high performance liquid chromatography technique. 
After ruling out active infection, pulmonary function test in the 
form of spirometry was done. Spirometry was also done in an equal 
number of age and sex matched control population. 
Spirometry was performed using a computerised easy one 
spirometer. Patient was made to sit, asked to wear a nose clip and  
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spirometry was performed according to American Thoracic Society 
recommendation.FVC or forced vital capacity,FEV1 or forced 
expiratory volume in 1St second,FEV1/FVC ratio or Forced expiratory 
ratio also known as FEV1% ,forced expiratory flow between 25 & 75 
% of FVC ,peak expiratory flow rate were measured. All these values 
of pulmonary function were compared with values in age and sex 
matched control population. Pulmonary function values were 
correlated with the duration of diabetes and level of glycemic control. 
HRCT, Bronchoscopy and other investigations were done 
wherever indicated. 
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                                       RESULTS 
Of the 150 patients in the study group 91 were males and 59 
were females.60% of the study group were symptomatic, of which 
37.3% were males & 22.7% were females. Of the symptomatics 
(n=90), 50% had pulmonary tuberculosis,33.3% had other bacterial 
and fungal infections , 16.6% had no active infection,60% mantoux 
negative& 40% were mantoux  positive. Of the pulmonary TB patients 
71.1% were sputum positive & 28.8 % were sputum negative.65.6% 
of sputum positive were mantoux positive. Radiologically most 
common finding in pulmonary TB was lower lung field TB. Klebsiella 
pneumonia was the most common bacterial infection other than TB. 
Pulmonary function tests were done in 60 asymptomatics& 15 
symptomatics without active infection and 75 age and sex matched 
control population. 
 
 
 
 
Of the 150 patients in the
39.33% were females
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 study population 60.67% were males an
 
d  
60% of the study populat
without symptoms. 
  Freque
Valid 
Yes 
No 
Total 
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ion had respiratory symptoms and 40% w
ncy Percent Valid Percent 
90 60.0 60.0 
60 40.0 40.0 
150 100.0 100.0 
ere 
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Gender  
Male Female Total 
Sym
ptom
s 
Yes 
 56 34 90 
% of Total 37.3% 22.7% 60.0% 
No 
Count 35 25 60 
% of Total 23.3% 16.7% 40.0% 
Total 
Count 91 59 150 
% of Total 60.7% 39.3% 100.0% 
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37.3% of males and 22.7 % of females were symptomatic. 
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Of the 90 symptomatics , 25.6% had normal chest x-ray, 15.6% had 
lower lung field tuberculosis,12.2% had multilobar 
involvement,23.3% had single lobar involvement. 
CXR FINDINGS IN THE SYMPTOMATICS 
 Frequency Percent 
Normal 23 25.6 
Lower Lung Field TB 14 15.6 
Multilobar 11 12.2 
Multiple Cavities 7 7.8 
Hydropneumothorax 5 5.6 
Single Lobar 21 23.3 
Lung Abscess 8 8.9 
Miliary TB 1 1.1 
Total 90 100 
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7.8% had multiple cavities in the chest x-ray,8.9% had lung  
abscess,1.1% had miliary shadows and 5.6% had hydropneumothorax 
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MANTOUX TEST RESULTS 
  Frequency Percent 
Valid Negative 54 60.0 
Positive 36 40.0 
Total 90 100.0 
 
 
 
 
 
 
 
 
Of the 90 symptomaticsmantoux test was positive in 60% andnegative 
in 40%. 
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Of the 90 symptomatics, 30 had bacterial infections other than 
tuberculosis,45 had pulmonary tuberculosis,15 had normal chest xray 
and no growth of any organisms in sputum. 
Sputum 
C&S 
 Frequency Valid Percent 
 
Klebsiella 15 50.0 
Pneumococci 7 23.3 
Con-staph 4 13.3 
Fungal 4 13.3 
Total 30 100.0 
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Of the bacterial infections,50% had klebsiella pneumonia 
,23.33% had pneumococcal infections,13.33% had coagulase negative 
staphylococci infections and another 13.33% had fungal 
infections.26.66% of patients with bacterial infections had normal 
chest x ray and were treated as acute bronchitis,remaining had 
multilobar, single lobar involvement, lung abscess etc. 
 
  CXR  
  
Single 
Lobar 
Lung 
Abscess 
Total 
Klebsiell
a 
 11 4 15 
% of Total 73.3% 26.7% 100.0% 
Total 
Count 11 4 15 
% of Total 73.3% 26.7% 100.0% 
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Out of 15 Klebsiella Pneumonia infections, 11 patients 
presented with single lobar pneumonia.(In this 6 cases  were Right 
upper lobe pneumonia) and 4 patients presented as lung abscess. 
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SPUTUM AFB RESULTS 
 Frequency Percent Valid Percent 
Negative 28 31.1 46.7 
Positive 32 35.6 53.3 
Total 60 66.7 100.0 
System 30 33.3  
Total 90 100.0  
 
 
 
 
 
Excluding 30 cases of bacterial infections out of the 90 symptomatics, 
sputum for AFB was positive in 53.3% and negative in 46.7%. 
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Out of 90 symptomatics,45 cases were diagnosed as pulmonary 
tuberculosis based on chest xray, sputum AFB and mantoux reports.  
Of the 45 TB cases 71.1% were sputum positive and 28.9% were 
sputum negative. 
SPUTUM AFB & PULMONARY TB 
  Frequency Percent 
Valid 
Negative 13 28.9 
Positive 32 71.1 
Total 45 100.0 
 
65.6%  of sputum positive pulmonary tuberculosis were mantoux 
positive. 
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MANTOUX AND PULMONARY TB 
  Frequency Percent 
Valid 
Negative 11 24.4 
Positive 34 75.6 
Total 45 100.0 
 
75.6% of pulmonary TB cases were mantoux positive and 24.4% 
weremantoux negative. 
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Of the 32 sputum positive pulmonary TB cases ,21 cases were 
mantoux positive and 11 cases were mantoux negative. The remaining 
13 sputum negative pulmonary TB cases were diagnosed on the basis 
of mantoux positivity and chest xray findings. 
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CXR PATTERN IN 
PULMONARY TB 
Frequency Percent 
Valid 
Lower Lung Field TB 14 31.1 
Multilobar 9 20.0 
Multiple Cavities 6 13.3 
Hydropneumothorax 5 11.1 
Single Lobar 7 15.6 
Lung Abscess 3 6.7 
Miliary TB 1 2.2 
Total 45 100.0 
 
Of the various radiological manifestations of pulmonary TB, most  
common was lower lung field TB .31.11% had lower lung field TB, 
20% had multilobar  ,15.56% had single lobar involvement,13.3 % 
had multiple cavities,11.11% had hydropneumothorax,6.67 % had 
multiple cavities and 2.2% had miliary TB. 
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Maximum sputum positivity among pulmonary TB cases were found  
with HbA1C in the range between 10-13 and  no sputum positive 
cases were found in those with good glycemic control (HbA1C <7). 
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PULMONARY TB & HbA1C LEVELS 
HbA1C   Yes No Total 
HbA1C 
Less than 7 
Count 0 8 8 
% of Total .0% 5.3% 5.3% 
7 - 10 
Count 11 50 61 
% of Total 7.3% 33.3% 40.7% 
10 - 13 
Count 27 38 65 
% of Total 18.0% 25.3% 43.3% 
More than 13 
Count 7 9 16 
% of Total 4.7% 6.0% 10.7% 
 Total 
Count 45 105 150 
% of Total 30.0% 70.0% 100.0% 
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                PULMONARY TB AND HbA1C LEVELS 
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HbA1 C BACTERIAL INFECTIONS 
Total 
Lessthan 
7 
Klebsiella Pneumococci 
Con-
staph 
Fungal 
0 (0%) 1 (3.3%) 0 (0%) 0 (0%) 
1 
(3.3%) 
7 -10 6 (20%) 6 (20%) 3 (10%) 0 (0%) 
15 
(50%) 
10- 13 8 (26.7%) 0 (0%) 1 (3.3%) 
4 
(13.3%) 
13 
(43.3%) 
More 
than 13 
1 (3.3%) 0 (0%) 0 (0%) 0 (0%) 
1 
(3.3%) 
Total 15 (50%) 7 (23.3%) 4 (13.3%) 
4 
(13.3%) 
30 
(100%) 
 
Bacterial infections were also more common in the HbA1C range  
between 10-13,of which klebsiella was most common. 
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Radiographic manifestations of pulmonary TB and bacterial  
infections were also more prominent in the HbA1C range of 10-13 
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DURATION OF DIABETES IN THE STUDY POPULATION 
  Frequency Percent 
Valid 
Newly Detected 31 20.7 
Less than 1 year 31 20.7 
1 - 5 years 44 29.3 
5 - 10 years 31 20.7 
More than 10 years 13 8.7 
Total 150 100.0 
Maximum number of cases were in the 1-5 year group 
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RELATION BETWEEN SPUTUM AFB POSITIVITY AND 
DIABETES DURATION 
 
Maximum number of sputum positive cases were seen in duration of 
diabetes less than 1 year. 
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PULMONARY TB AND DURATION OF DIABETES 
   TB  
Duration 
of 
Diabetes 
Newly Detected Count 13 18 31 
 
 
 
Less than 1 year 
% of Total 8.7% 12.0% 20.7% 
Count 12 19 31 
 
1 - 5 years 
% of Total 8.0% 12.7% 20.7% 
Count 8 36 44 
 
5 - 10 years 
% of Total 5.3% 24.0% 29.3% 
Count 10 21 31 
 
More than 10 
years 
% of Total 6.7% 14.0% 20.7% 
Count 2 11 13 
 
Total 
% of Total 1.3% 7.3% 8.7% 
Count 45 105 150 
  
% of Total 30.0% 70.0% 100.0% 
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RESULTS OF PULMO	ARY FU	CTIO	 TEST 
CORRELATION BETWEEN PULMONARY FUNCTION TEST 
AND DURATION OF DIABETES 
 
 
 
 
 
 
 
 
 
 
 
 
  
PULMONARY 
FUNCTION TEST 
Duration of 
Diabetes 
 
FEV1 
Correlation 
Coefficient 
-.464** 
Sig. (2-tailed) .000 
N 75 
FVC 
Correlation 
Coefficient 
-.370** 
Sig. (2-tailed) .001 
N 75 
FEV1 / FVC 
Correlation 
Coefficient 
-.331** 
Sig. (2-tailed) .004 
N 75 
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CORRELATION BETWEEN PULMONARY FUNCTION TEST 
AND HbA1C LEVELS 
 
PULMONARY FUNCTION 
TEST 
HbA1C 
FEV1 
Correlation Coefficient .000 
Sig. (2-tailed) .996 
N 75 
FVC 
Correlation Coefficient .008 
Sig. (2-tailed) .946 
N 75 
FEV1 / FVC 
Correlation Coefficient .112 
Sig. (2-tailed) .340 
N 75 
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COMPARISON BETWEEN FEV1 IN DIABETIC PATIENTS AND 
NON DIABETIC CONTROLS 
  FEV1 FEV1 - Control 
FEV1 Pearson 
Correlation 
1 .802** 
Sig. (2-tailed)  .000 
N 75 75 
FEV1 - 
Control 
Pearson 
Correlation 
.802** 1 
Sig. (2-tailed) .000  
N 75 75 
 
Forced expiratory volume in the 1st second FEV1 shows 
statistically significant decrease in diabetic patients compared  
tonon diabeticcontrols(pvalue<0.01) 
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COMPARISON OF FVC BETWEEN PATIENTS AND CONTROLS 
  FVC FVC - Control 
FVC 
Pearson Correlation 1 .697** 
Sig. (2-tailed)  .000 
N 75 75 
FVC - Control 
Pearson Correlation .697** 1 
Sig. (2-tailed) .000  
N 75 75 
 
**. Correlation is significant at the 0.01 level (2-tailed). 
Forced vital capacity also shows  reduction that is statistically 
significant in patients compared to controls 
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COMPARISON OF FEV1/FVC BETWEEN DIABETIC PATIENTS 
AND NON DIABETIC CONTROLS 
FEV1 / FVC 
Pearson 
Correlation 
1 .267* 
Sig. (2-tailed)  .021 
N 75 75 
FEV1 / FVC - 
Control 
Pearson 
Correlation 
.267* 1 
Sig. (2-tailed) .021  
N 75 75 
 
 Correlation is significant at the 0.05 level (2-tailed). 
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DISCUSSIO	 
This study was mainly done to assess the pulmonary 
manifestations including pulmonary functions in type 2 
diabetes mellitus. Main emphasis was given on pulmonary 
function in asymptomatic diabetics and symptomatics without 
active infection. This was then compared with non-diabetic 
age and sex match control population.  
Duration of diabetes in the study group ranged from 1 
month to 30 years. Glycosylated haemoglobin was done in all 
patients to assess the glycemic control, since many studies 
showed that poor glycemic control had an adverse effect on 
lung function. FEV1 values were lower in diabetics compared 
to non diabetic controls with a p value<0.05 .These findings 
were similar to that of Asanuma et al (16), SanjeevSinha et 
al(27),Lange et al studies. This decrease may be due to 
alveolar epithelium and capillary endothelium, basement 
membrane thickening and decreased elastic recoil of the lung. 
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Forced vital capacity values also showed statistically 
significant reduction in diabetics than non diabetic controls. 
Similar findings were observed in Makkar P et al(36), 
Mckeer et al , Sanjeev et al,Maurizio(8) et al studies. This 
reduction in FVC may be due to glycated proteins in 
connective tissue that decrease the elastic recoil of the lung as 
well as pulmonary microangiopathy. 
All the spirometric parameters showed significant 
reduction correlating with the duration of diabetes. Since 
HbA1c levels reflects glycemic control over a period of only 
3 months, no significant correlation was found between 
pulmonary functions and HbA1C. This finding was against 
Davis et al(38) studies that showed decreased lung function 
associated with poor glycemic control. 
 Several studies also demonstrated decrease in PEFR 
due to decreased capacity of respiratory muscles, decreased 
FEF 25-75% and also decrease in maximum voluntary 
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ventilation (MVV) due to decreased respiratory muscle 
endurance.  
Among infections in diabetes mellitus , pulmonary TB 
was most common. Most common radiological pattern in 
pulmonary TB was lower lung field involvement. This was 
similar to the results of the largest study done about 
radiological manifestations in TB-PerenzGusman(24) et al 
study, which showed increased lower lung field lesions. 
Multiple cavities were another common presentations in 
diabetics.  
Several studies showed that risk of developing sputum 
positive pulmonary TB is five times higher in diabetics. Of 
the 45 pulmonary TB patients ,32 were sputum positive in the 
study group. Diabetes cause immune suppression that results 
in high bacillary load in TB patients with diabetes. 
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Bacterial infections are also more common in diabetics 
and associated with higher mortality. Most common bacterial 
pathogen other than TB causing disease in the study group  
was Klebsiella pneumoniae. 
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CO	CLUSIO	 
• Pulmonary function tests FEV1 and FVC are reduced in 
diabetics, compared to non diabetic control population. 
• Reduction in FEV1 And FVC correlates with the duration 
of diabetes, but not with HbA1C levels. 
• Lung involvement in asymptomatic diabetics can be 
assessed by pulmonary function test. 
•  Diabetics are more susceptible to pulmonary 
tuberculosis, recurrent pneumonia associated with higher 
mortality rates, fungal infections due to alteration in host 
defence, respiratory epithelium function and cilia motility.  
• Most common bacterial infection in diabetes was 
pulmonary tuberculosis followed by klebsiella pneumonia 
infection 
 Elevated blood glucose levels negatively affect the 
outcome in pneumonia as well as other infections. The 
importance of optimal glycemic control and its effect on 
the respiratory system can be assessed,thus the adverse 
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outcome on the lung  due to uncontrolled diabetes can be 
reduced. 
 As the prevalence of type 2 diabetes reaches epidemic 
proportions, the pathophysiology of lung involvement 
in diabetes assumes greater relevance. 
 In future we can extend the study by including DLCO, 
respiratory pressures, non volatile tests in a large sample 
group for more accurate assessment of pulmonary 
function in diabetics. 
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 I	FORMATIO	 SHEET 
 We are conducting an observational study on “Evaluation of 
pulmonary manifestations in Type2 Diabetes mellitus and 
correlation between pulmonary function tests and 
glycemiccontrol” at Department of Thoracic Medicine, Madras 
Medical College and Rajiv Gandhi Government General 
Hospital, Chennai. 
 The purpose of the study is to evaluate the various clinical and 
radiological pulmonary manifestations in diabetes mellitus and 
to study the correlation between pulmonary function in diabetic 
patients based on PFT values and glycemic control assessed by 
FBS , PPBS, HbA1C. 
 The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or 
presentation resulting from the research, no personally 
identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; 
your decision will not result in any loss or benefits to which you 
are otherwise entitled. 
 The results of the special study may be intimated to you at the 
end of the study period or during the study if anything is found 
abnormal which may aid in the management or treatment. 
 
 
Signature of investigator     Signature of participant  
                
 
Date: 
 
  
PATIE	T CO	SE	T FORM 
Study Details  :“Evaluation Of Clinic oradiological  Pulmonary 
Manifestations In Type 2  Diabetes Mellitus and Correlation  Between Pulmonary 
Function Test and Glycemic Control” at Madras Medical College and Rajiv 
Gandhi Government General Hospital ,Chennai. 
Study Centre :   Department of Thoracic Medicine and Diabetology, Madras 
Medical College, Chennai. 
Patient may check(√) these boxes  
I confirm that I understood the purpose of procedure for the above 
study.Ihave the opportunity at ask question and all my questions and doubts have 
been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal rights being 
affected. 
I understand that the sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will not 
need my permission to look at my health records, both in respect of current study 
and any further research that may be conducted in relation to it, even if I withdraw 
from my study I agree to this access. However, I understand that my identity will 
not be revealed in any information released to third parties or published , unless as 
required under the law. I agree not to restrict the use of any data or results that 
arise from this study. 
I agree to take part in the above study and comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff  if I suffer from any deterioration in my health 
or wellbeing or any unexpected or unusual symptoms. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including haematological, biochemical, radiological and 
pulmonary function test. I hereby consent to participate in the study. 
Signature/Thumb impression 
Patient name and address:     Signature of investigator: 
Date: Place:      Study Investigator’s name : 
Date : 
  
PROFORMA 
	ame of the patient: 
Age :                                            Sex:                     Date: 
Presenting  Complaints: 
Duration of diabetes  : 
Type of Diabetes        :      Type 1  / Type II   
 On:                OHA   /   Insulin 
Past H/o Respiratory Disease:        Yes  /  	o 
Past H/o heart disease: 
Smoker: 
Investigations: 
        CBC: Hb PCV                            TC    
        DC    RBC                                   ESR 
RFT:B.Urea S.Creatinine 
LFT:S.Bilirubin 
SGOT: 
SGPT:   
T.Protein: 
FBS :                           PPBS:                                          HbA1C  : 
Mantoux 
 
  
Sputum AFB: 
Sputum C/S 
Sputum Fungal Smear: 
Echo/ ECG: 
CXR  : 
PFT  : 
HRCT: 
Bronchoscopy : 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
